NCT05355701 2026-03-27A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.PfizerPhase 1 Recruiting267 enrolled
NCT05538130 2026-03-27A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid TumorsPfizerPhase 1 Recruiting124 enrolled
NCT05199584 2026-03-05A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function MutationsEndeavor Biomedicines, Inc.Phase 2 Completed20 enrolled
NCT06270082 2025-09-19Study of IK-595 in RAS- or RAF-altered Advanced TumorsIkena OncologyPhase 1 Terminated75 enrolled
NCT04521686 2025-06-27Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 MutationsEli Lilly and CompanyPhase 1 Active not recruiting200 enrolled
NCT05500508 2024-12-24Oral AMXT 1501 Dicaprate in Combination With IV DFMOAminex Therapeutics, Inc.Phase 1/2 Terminated15 enrolled
NCT02034110 2023-08-21Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare CancersNovartisPhase 2 Completed206 enrolled 40 charts 4 FDA
NCT00565721 2014-08-18A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and AngiogenesisGE HealthcarePhase 2 Completed33 enrolled 23 charts
NCT00538850 2014-03-05Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainINSYS Therapeutics IncPhase 3 Completed130 enrolled 9 charts